• Appointment of new Scientific Advisory Board comprising thought leaders from academia and industry to boost pipeline progress and expansion
• New laboratories will accommodate growing team and increased activities
• Move supported by key shareholder Noshaq and SPI and confirms Imcyse’s commitment to the Walloon Region of Belgium, a leading center for talent and R&D within Europe

From start on, a major goal of INNODIA was to undertake clinical intervention studies and to pave the way for the development of novel treatments to prevent and cure Type 1 Diabetes.

INNODIA is now performing mechanistic-based clinical studies, using a Master-Protocol established within INNODIA.

• Pfizer takes equity stake in Imcyse as part of the recently announced Rheumatoid Arthritis license agreement
• Major existing shareholders participated in the round
• Proceeds to advance Imcyse’s pipeline of first-in-class targeted disease modifying immunotherapeutics

Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases, today enters into Research Collaboration and License Agreement for its Imotope™ Technology with Pfizer in Rheumatoid Arthritis

• Imcyse and Pfizer to collaborate to develop Imotope™ candidates to potentially treat Rheumatoid Arthritis

• Pfizer to lead clinical development and commercialization activities

• Imcyse to receive upfront payment in cash and through the purchase of equity in addition to milestone up to $180 million and tiered royalty payments

Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases, today announced Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes.Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases, today announced Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes.